Ultragenyx Pharmaceutical's Upcoming Investor Conferences in December
Ultragenyx Pharmaceutical's Upcoming Investor Conferences
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) is preparing for an exciting month ahead as they participate in several key investor conferences. This biopharmaceutical company specializes in developing and commercializing advanced therapies for rare and ultrarare genetic diseases and is eager to share its progress with the investment community.
Citi's 2024 Global Healthcare Conference
The first event on the agenda is the Citi's 2024 Global Healthcare Conference. Scheduled for December 3, 2024, in a vibrant location, the conference will feature Emil Kakkis, M.D., Ph.D., the CEO and President of Ultragenyx, alongside Howard Horn, the Chief Financial Officer. These leaders will engage in a fireside chat and partake in one-on-one meetings with investors, providing insights into the company’s latest developments and future direction.
7th Annual Evercore ISI HealthCONx Conference
Following the Citi conference, on December 4, 2024, Ultragenyx will attend the 7th Annual Evercore ISI HealthCONx Conference. During this conference, Emil Kakkis and Howard Horn will again participate in a fireside chat and hold further one-on-one investor meetings, discussing the company’s advancements and strategic goals.
Piper Sandler's 36th Annual Healthcare Conference
The excitement continues on December 5, 2024, with Piper Sandler's 36th Annual Healthcare Conference. Eric Crombez, M.D., the Chief Medical Officer, along with Howard Horn, will represent Ultragenyx, delivering a fireside chat and engaging in one-on-one discussions with key stakeholders. This event marks an excellent opportunity for investors to connect with the company’s leadership and delve deeper into the innovative work Ultragenyx is doing in the field of rare diseases.
Future Directions in Rare Disease Therapeutics
Ultragenyx is dedicated to transforming the treatment landscape for patients afflicted with rare genetic disorders. The company's mission revolves around developing safe and effective therapies targeted at conditions that are often overlooked by conventional pharmaceutical companies. Its commitment is evident in its diverse portfolio of approved therapies and product candidates, each designed to address diseases that lack available treatments.
About Ultragenyx Pharmaceutical Inc.
Ultragenyx stands out in the biopharmaceutical industry for its dedication and innovative approach. The management team comprises seasoned professionals with substantial experience in bringing rare disease therapeutics to market efficiently and effectively. This focus on time-sensitive drug development ensures that the benefits of discovery are realized promptly for patients in critical need.
Company Information and Contact
Individuals seeking more information about Ultragenyx are encouraged to visit their official website. There, stakeholders can access additional resources, including a section dedicated to investor relations, which outlines the company's objectives and ongoing projects.
For investor inquiries, Joshua Higa, who handles investor relations at Ultragenyx, is readily available. You can reach him via email at ir@ultragenyx.com for any questions or further information.
Frequently Asked Questions
What is Ultragenyx Pharmaceutical Inc. known for?
Ultragenyx Pharmaceutical is known for developing therapies for serious rare and ultrarare genetic diseases.
When will Ultragenyx attend investor conferences?
Ultragenyx will attend three investor conferences in December 2024, starting on the 3rd.
Who are the key executives participating in the conferences?
Emil Kakkis, M.D., Ph.D., and Howard Horn will participate in the first two conferences, while Eric Crombez, M.D., will join for the third.
What is the goal of Ultragenyx in attending these conferences?
The goal is to engage with investors and showcase the company’s advancements in treating rare genetic diseases.
How can investors learn more about Ultragenyx’s activities?
Investors can visit Ultragenyx's website or contact the investor relations team for detailed information.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.